Literature DB >> 21938742

Cellular distribution of Glut-1 and Glut-5 in benign and malignant human prostate tissue.

Karin Reinicke1, Paula Sotomayor, Pedro Cisterna, Carolina Delgado, Francisco Nualart, Alejandro Godoy.   

Abstract

Over-expression of hexose transporters (Gluts), specifically Glut-1, is a common event in human malignancies. In prostate cancer (CaP), however, expression of Gluts has been characterized poorly. In this study, expression and distribution of Glut-1 and Glut-5 proteins were characterized using immunohistochemistry in 76 specimens of benign prostate, 10 specimens of high-grade intraepithelial neoplasia (HGPIN), and 28 specimens of CaP. In addition, mRNA expression of Glut-2, Glut-7, Glut-9, and Glut-11 was analyzed in a set of five specimens of benign prostate and CaP. In benign prostate, Glut-1 localized to the basal cells and to the basolateral membrane of secretory/luminal epithelial cells. Glut-5, however, localized to the apical membrane of secretory/luminal epithelial cells. In HGPIN, Glut-1 was immunohistochemically undetectable. Glut-5, however, localized to the apical membrane of the neoplastic epithelial cells. In CaP, Glut-1 and Glut-5, were immunohistochemically undetectable. However, over-expression of GLUT1 was observed in some specimens of highly proliferative intraductal CaP. Glut-7, Glut-9, and Glut-11 mRNAs were detected in benign prostate and CaP, however, only Glut-11 mRNA was consistently up-regulated in CaP compared to benign prostate. Low levels of expression of Glut-1 protein in the majority of CaP could explain, at least in part, the limited clinical applicability of positron emission tomography using 2-[18F]-fluoro-2-deoxy-D-glucose for imaging CaP. Moreover, expression of Glut-5 in HGPIN suggested that fructose could be utilized as potential metabolic substrate in HGPIN. Understanding the molecular mechanisms involved in regulation/dysregulation of Gluts in CaP could provide insight in the understanding of hexose metabolism in CaP.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21938742     DOI: 10.1002/jcb.23379

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  24 in total

1.  Multicentre study of 18F-FDG-PET/CT prostate incidental uptake.

Authors:  Francesco Bertagna; Arnoldo Piccardo; Bassam Dib; Mattia Bertoli; Federica Fracassi; Giovanni Bosio; Raffaele Giubbini; Giorgio Biasiotto; Luca Giovanella; Giorgio Treglia
Journal:  Jpn J Radiol       Date:  2015-07-08       Impact factor: 2.374

Review 2.  Molecular imaging of prostate cancer: PET radiotracers.

Authors:  Hossein Jadvar
Journal:  AJR Am J Roentgenol       Date:  2012-08       Impact factor: 3.959

3.  (18)F-FDG-PET/CT and (18)F-NaF-PET/CT in men with castrate-resistant prostate cancer.

Authors:  Katherine A Zukotynski; Chun K Kim; Victor H Gerbaudo; Jon Hainer; Mary-Ellen Taplin; Philip Kantoff; Annick D Van den Abbeele; Steven Seltzer; Christopher J Sweeney
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-12-15

4.  Clinical significance of incidental FDG uptake in the prostate gland detected by PET/CT.

Authors:  Ertan Sahin; Umut Elboga; Ebuzer Kalender; Mustafa Basıbuyuk; Hasan Deniz Demir; Yusuf Zeki Celen
Journal:  Int J Clin Exp Med       Date:  2015-07-15

Review 5.  Molecular aspects of fructose metabolism and metabolic disease.

Authors:  Mark A Herman; Morris J Birnbaum
Journal:  Cell Metab       Date:  2021-10-06       Impact factor: 27.287

6.  Multitarget Molecular Imaging in Metastatic Castration Resistant Adenocarcinoma Prostate Cancer with Therapy Induced Neuroendocrine Differentiation.

Authors:  Joel Vargas Ahumada; Sofía D González Rueda; Fabio A Sinisterra Solís; Quetzali Pitalúa Cortés; Liliana P Torres Agredo; Jimenez Ríos Miguel; Anna Scavuzzo; Irma Soldevilla-Gallardo; Miguel A Álvarez Avitia; Nora Sobrevilla; Francisco Osvaldo García Pérez
Journal:  Diagnostics (Basel)       Date:  2022-06-03

Review 7.  Glucose transporters in cancer metabolism.

Authors:  Kehinde Adekola; Steven T Rosen; Mala Shanmugam
Journal:  Curr Opin Oncol       Date:  2012-11       Impact factor: 3.645

8.  Hyperpolarized [1-13C]dehydroascorbate MR spectroscopy in a murine model of prostate cancer: comparison with 18F-FDG PET.

Authors:  Kayvan R Keshari; Victor Sai; Zhen J Wang; Henry F Vanbrocklin; John Kurhanewicz; David M Wilson
Journal:  J Nucl Med       Date:  2013-04-10       Impact factor: 10.057

9.  Purine nucleotide metabolism regulates expression of the human immune ligand MICA.

Authors:  Michael T McCarthy; Gerard Moncayo; Thomas K Hiron; Niels A Jakobsen; Alessandro Valli; Tomoyoshi Soga; Julie Adam; Christopher A O'Callaghan
Journal:  J Biol Chem       Date:  2017-12-26       Impact factor: 5.157

10.  PTEN dephosphorylates AKT to prevent the expression of GLUT1 on plasmamembrane and to limit glucose consumption in cancer cells.

Authors:  Suratchanee Phadngam; Andrea Castiglioni; Alessandra Ferraresi; Federica Morani; Carlo Follo; Ciro Isidoro
Journal:  Oncotarget       Date:  2016-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.